We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
+39.75%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$165M
AUM Growth
+$52.7M
Cap. Flow
+$21.1M
Cap. Flow %
12.75%
Top 10 Hldgs %
78.72%
Holding
53
New
7
Increased
8
Reduced
3
Closed
2

Top Buys

Rank Stock Value
1
AWH
Aspira Women's Health Inc. Common Stock
AWH
+$14.7M
2
BLUE
bluebird bio
BLUE
+$3.49M
3
SLNO
Soleno Therapeutics
SLNO
+$1.81M
4
ETRN
Equitrans Midstream Corporation Common Stock
ETRN
+$1.05M
5
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$834K

Top Sells

Rank Stock Value
1
VRML
Vermillion, Inc.
VRML
+$2.68M
2
GILD icon
Gilead Sciences
GILD
+$766K
3
EQM
EQM Midstream Partners, LP
EQM
+$605K
4
IFRX icon
InflaRx
IFRX
+$259K
5
WKHS icon
Workhorse Group
WKHS
+$32.5K

Sector Composition

Rank Sector Weight
1 Healthcare 95.54%
2 Energy 1.09%
3 Consumer Discretionary 0.16%
4 Consumer Staples 0.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VNDA icon
26
Vanda Pharmaceuticals
VNDA
$323M
$915K 0.55%
80,000
– –
IMGN
27
DELISTED
Immunogen Inc
IMGN
$874K 0.53%
190,000
– –
ODT
28
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$847K 0.51%
20,000
– –
CORT icon
29
Corcept Therapeutics
CORT
$9.87B
$841K 0.51%
50,000
– –
GILD icon
30
Gilead Sciences
GILD
$166B
$769K 0.46%
10,000
-10,000
-50% -$766K
BHVN
31
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$731K 0.44%
10,000
– –
CLR
32
DELISTED
CONTINENTAL RESOURCES INC.
CLR
$677K 0.41%
+38,600
New +$542K
FOLD
33
DELISTED
Amicus Therapeutics
FOLD
$573K 0.35%
38,000
– –
TBIO
34
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$538K 0.33%
30,000
– –
ARVN icon
35
Arvinas
ARVN
$517M
$503K 0.3%
15,000
– –
NARI
36
DELISTED
Inari Medical, Inc. Common Stock
NARI
$484K 0.29%
+10,000
New +$478K
STOK icon
37
Stoke Therapeutics
STOK
$1.74B
$477K 0.29%
20,000
– –
XNCR icon
38
Xencor
XNCR
$1.4B
$398K 0.24%
12,300
– –
ICPT
39
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$398K 0.24%
8,300
– –
PGNY icon
40
Progyny
PGNY
$2.51B
$387K 0.23%
15,000
– –
VYGR icon
41
Voyager Therapeutics
VYGR
$187M
$379K 0.23%
30,000
– –
PXD
42
DELISTED
Pioneer Natural Resource Co.
PXD
$371K 0.22%
3,800
– –
KALV
43
DELISTED
KalVista Pharmaceuticals
KALV
$363K 0.22%
30,000
– –
OVV icon
44
Ovintiv
OVV
$16.5B
$328K 0.2%
+34,350
New +$240K
IFRX icon
45
InflaRx
IFRX
$271M
$321K 0.19%
70,000
-40,000
-36% -$259K
TGTX icon
46
TG Therapeutics
TGTX
$8.39B
$292K 0.18%
15,000
– –
APLS
47
DELISTED
Apellis Pharmaceuticals
APLS
$261K 0.16%
8,000
– –
WKHS icon
48
Workhorse Group
WKHS
$30.1M
$261K 0.16%
5
-3
-38% -$32.5K
DRNA
49
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$254K 0.15%
10,000
– –
YTEN
50
DELISTED
Yield10 Bioscience, Inc. Common Stock
YTEN
$118K 0.07%
790
– –
1
2
3

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
FPW
Flywheel Private Wealth Los Altos, California $176M AUM 26.12% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return

Birchview Capital's Q2 2020 Portfolio in Review

As of Q2 2020, Birchview Capital held 53 positions worth $165M, up 47% from $113M the previous quarter. Its ten largest holdings account for 79% of the portfolio.

Birchview Capital deployed $21.1M of net new capital in Q2 2020, opening 7 new positions and adding to 8 existing holdings. Its largest new stake was Aspira Women's Health Inc. Common Stock: 219,816 shares worth $12.7M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 96% a quarter earlier, followed by Energy and Consumer Discretionary.

On the sell side, the largest reduction was Gilead Sciences, an estimated $766K trimmed.

  • Birchview Capital's largest Q2 2020 buy was Aspira Women's Health Inc. Common Stock: 219,816 shares worth $12.7M.
  • Birchview Capital added most to Soleno Therapeutics in Q2 2020, an estimated $1.81M increase.
  • Birchview Capital's biggest Q2 2020 reduction was Gilead Sciences, cutting an estimated $766K.
  • Birchview Capital fully exited Vermillion, Inc. in Q2 2020, selling an estimated $2.68M.
  • Birchview Capital's ten largest holdings make up 79% of its $165M portfolio in Q2 2020.
  • Birchview Capital opened 7 new positions and closed 2 in Q2 2020.
  • Birchview Capital's portfolio value rose 47% quarter-over-quarter to $165M.

Based on Birchview Capital's 13F filing for Q2 2020, filed 10 Aug 2020.